Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.77 |
| ▸ | MAOB | P27338 | 8/20 | 0.77 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.59 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | PTGES | O14684 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29530200 | 0.90 | MAOB (0.64) | MAOAMAOBPTPN1PTPN2PTGES | |
| SCHEMBL27707705 | 0.83 | MAOB (0.55) | MAOAMAOBNPC1CASP3RAB9A | |
| SCHEMBL1998830 | 0.82 | MAOB (0.62) | MAOAMAOBPTPN1PTPN2PTGS2 | |
| SCHEMBL7956495 | 0.80 | MAOB (0.79) | MAOAMAOBPKML3MBTL1CASP3 | |
| SCHEMBL23707607 | 0.80 | PTGES (0.53) | MAOAMAOBPKML3MBTL1PTGES | |
| SCHEMBL20483281 | 0.80 | NR1H4 (0.57) | MAOAMAOBPKML3MBTL1PTGES | |
| SCHEMBL7944024 | 0.80 | MAOA (0.60) | MAOAMAOBPTPN1PTPN2PTGS2 | |
| SCHEMBL27516743 | 0.78 | MAOA (0.57) | MAOAMAOBPKML3MBTL1CASP3 | |
| SCHEMBL1572774 | 0.77 | MAOB (0.71) | MAOAMAOBPTPN1PTPN2PTGS2 | |
| SCHEMBL7950720 | 0.76 | MAOB (0.79) | MAOAMAOBPKML3MBTL1PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297176-B2 | Compounds and methods for inhibiting EMT pathways to treat cancer, organ fibrosis and metabolic disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-05-13 | — | — | US | disclosed |
| US-20220017466-A1 | COMPOUNDS AND METHODS FOR INHIBITING EMT PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-01-20 | — | — | US | disclosed |
| US-20220017466-A1 | COMPOUNDS AND METHODS FOR INHIBITING EMT PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-01-20 | — | — | US | disclosed |
| US-11078159-B2 | Compounds and methods for inhibiting EMT pathways to treat cancer, organ fibrosis and metabolic disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-08-03 | — | — | US | disclosed |
| US-11078159-B2 | Compounds and methods for inhibiting EMT pathways to treat cancer, organ fibrosis and metabolic disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-08-03 | — | — | US | disclosed |
| WO-2018156459-A1 | COMPOUNDS AND METHODS FOR INHIBITING EMT PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-08-30 | — | — | WO | disclosed |
| US-6218427-B1 | AS ENDOTHELIN RECEPTOR ANTAGONIST | SHIONOGI & CO., LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| CN-1234029-A | Chromene-3-carboxylate derivative | SHIONOGI & CO (JP) | 1999-11-03 | — | — | CN | disclosed |
| EP-0924207-A1 | CHROMENE-3-CARBOXYLATE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 1999-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297176-B2 | Compounds and methods for inhibiting EMT pathways to treat cancer, organ fibrosis and metabolic disorders | HGF, SMAD3, HRAS | MAOA 4663/4885MAOB 4207/4885PTPN1 3234/4885 |
| US-11078159-B2 | Compounds and methods for inhibiting EMT pathways to treat cancer, organ fibrosis and metabolic disorders | HGF, SMAD3, HRAS | MAOA 4663/4885MAOB 4207/4885PTPN1 3234/4885 |
| US-20220017466-A1 | COMPOUNDS AND METHODS FOR INHIBITING EMT PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS | HGF, SMAD3, HRAS | MAOA 4663/4885MAOB 4207/4885PTPN1 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.